News & events

News & events

Filter by:
  • News

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001

Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling...

  • News

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m...

  • Conferences & Events

VarmX to present at LSX Investival Showcase

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...
  • Management TeamNews

VarmX announces appointment of John Glasspool as CEO

Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company...

  • Management TeamNews

VarmX announces appointment of Martijn Negen as COO

Leiden, The Netherlands, 10 september 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...

  • Conferences & Events

VarmX Presents New Data at ISTH 2024

Leiden, The Netherlands, 26 June 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...

  • Conferences & Events

VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...
  • Scientific publications

Coagulation assays for assessing direct FXa inhibitor oral anticoagulant reversal effect

Factor Xa direct oral anticoagulants (Fxa-DOACs) require rapid reversal in patients with serious bleeding or prior to urgent surgery.

...
  • Conferences & Events

VarmX to Present Two Abstracts on Lead Compound, VMX-C001, at ISTH 2023 Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...
  • News

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has...
  • News

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio